Eosinophilic gastroenteritis (EoGE) can be diagnosed on the basis of histologic criteria; however, the pathology is considered to be heterogeneous. There is no consensus on the management of this enigmatic disorder with an unknown etiology.
Data for patients diagnosed with EoGE and followed up over a 1-year period were analyzed. Their symptoms, patterns of flares, and type of treatment were documented. The shift in peripheral blood eosinophil levels was also examined.
A total of 10 (mean age, 44 years; range: 31–70 years; women, 5) patients were diagnosed with EoGE. The most frequent presenting symptom was abdominal pain, and eight patients were classified with mucosal type of EoGE. Chronic disease or multiple flares were observed in seven out of 10 (70.0%) patients, and all of them had a history of allergy. Four were corticosteroid dependent (three relapsed during corticosteroid tapering and one following corticosteroid withdrawal). One of them received anti-IL5 monoclonal antibody that enabled corticosteroid dose tapering. In four patients with highly elevated initial eosinophil levels at diagnosis, the peripheral eosinophil level correlated with the amelioration and deterioration of their symptoms. The remaining three patients had a single flare without relapse. Two had no history of allergy.
EoGE is a unique disorder with a variable clinical course. Although further studies are required to confirm our observations, the presence of other allergic disorders is associated with chronicity or multiple flares. Peripheral eosinophil level may be an effective biomarker for recurrence in patients with severe systemic disorders at diagnosis.
aDepartment of Gastroenterology, Saiseikai Niigata Daini Hospital
bDivision of Gastroenterology and Hepatology, Niigata University Medical and Dental Hospital, Niigata, Japan
Correspondence to Hiroki Sato, MD, PhD, Department of Gastroenterology, Saiseikai Niigata Daini Hospital, 280-7 Teraji, Niigata 950-1104, Japan Tel: +81 25 233 6161; fax: +81 25 233 8880; e-mail: email@example.com
Received June 8, 2018
Accepted July 9, 2018